Job Description Primary Function of Position: Reporting to the Director of Evidence Strategy and Access, Europe, within the Medical Affairs team. You will collaborate closely with Sales, Clinical Affairs, and the Global Access Value and Economics teams to develop robust frameworks for the assessment and appraisal of robotics‑assisted technologies. Leads market access, reimbursement, and funding activities for established therapies and rapidly evolving technologies across Germany, Switzerland, and Austria (DACH). Defines and strategically shapes the most appropriate access pathways—including coverage mechanisms (e.g. DRGs, procedure codes, add‑on payments), HTA high‑quality submissions, and funding negotiations—to support timely adoption of MedTech and capital equipment in both hospital and ambulatory settings. Establish and build a strong network of relevant opinion leaders across providers, payers, and policymakers. Manage relationships with key national and local stakeholders, working closely with Key Opinion Leaders and scientific societies to strengthen engagement, advocacy, and alignment in discussions with national payer and reimbursement decision‑makers. Leading the initiation and governance of consultancy engagements across a broad portfolio of market access initiatives Roles and Responsibilities: Securing optimal reimbursement, ensuring our solutions are properly coded, covered, and funded across the region. Analyze funding pathways, evaluate policy and payment system changes, and translate them into actionable strategies that support clinical adoption and commercial success. Establish and build network of relevant opinion leaders across a broad range of providers, payers and policy makers. Develop and execute strategies for market access at national and local level Leads, coordinates, or supports HTA activities, including the preparation and submission of national or regional HTA dossiers, engagement with assessment bodies, and alignment of clinical and economic evidence. Acts as the primary HTA expert for robotics‑assisted bronchoscopy BU Strategically leverages clinical data and real‑world evidence (RWD) to inform and shape market access strategies, strengthening value narratives to support coverage, reimbursement, and funding objectives across the region.